Why Your Arteries Stiffen With Age and How to Fight Back

Cardiovascular disease kills roughly 17.9 million people annually—nearly a third of all global deaths—and arterial stiffness sits at the mechanistic center of this crisis. This 2025 review in Signal Transduction and Targeted Therapy synthesizes decades of research to provide a detailed, translational account of how arteries stiffen over a lifetime and what clinicians and researchers can do about it.

The review begins with anatomy. Large arteries consist of three concentric layers—the tunica intima (endothelial monolayer), tunica media (predominantly vascular smooth muscle cells, elastin, and collagen), and tunica adventitia (fibroblasts, immune cells, connective tissue)—surrounded by perivascular adipose tissue (PVAT). The tunica media is the primary determinant of arterial stiffness. With aging, elastin fibers fatigue and fragment, collagen accumulates and undergoes advanced glycation end-product (AGE)-mediated crosslinking, VSMCs shift from a contractile to a synthetic/osteogenic phenotype, and medial calcification deposits calcium-phosphate mineral that further rigidifies the wall. Endothelial dysfunction—characterized by reduced nitric oxide bioavailability, increased reactive oxygen species, and a proinflammatory, prothrombotic state—accelerates these structural changes.

Two underappreciated contributors receive special attention. Perivascular adipose tissue, once considered passive insulation, is now recognized as an active paracrine organ. In lean, healthy states PVAT releases adiponectin and nitric oxide to protect vascular tone; with obesity and aging, it shifts toward a proinflammatory, pro-oxidative secretome that drives medial stiffening. Extracellular vesicles (EVs)—nanosized membrane particles shed by all vascular cells—carry bioactive cargo (miRNAs, proteins, lipids) that modulates VSMC phenotype, promotes calcification, and propagates endothelial injury both locally and systemically. EVs are emerging as both mechanistic mediators and potential liquid-biopsy biomarkers of arterial stiffness.

Functionally, stiff arteries lose their Windkessel buffering capacity: the aorta can no longer absorb systolic pressure peaks and release them smoothly in diastole. The result is elevated pulse pressure, isolated systolic hypertension, increased cardiac afterload, impaired coronary perfusion (coronary filling occurs in diastole), and amplified pulsatile stress transmitted to low-resistance microvascular beds in the brain, kidneys, and retina. End-organ consequences include heart failure with preserved ejection fraction, vascular dementia, chronic kidney disease, and hypertensive retinopathy. The review underscores that arterial stiffness predicts these outcomes independently of traditional risk factors.

For measurement, carotid-femoral pulse wave velocity (cf-PWV) remains the gold standard, with a threshold of ≥10 m/s indicating elevated risk in guidelines. Complementary methods include augmentation index, central blood pressure, flow-mediated dilation, and imaging modalities. On the therapeutic side, the authors review evidence for aerobic exercise (particularly high-intensity interval training), dietary patterns (Mediterranean, DASH), blood pressure-lowering agents (especially ACE inhibitors and ARBs), statins, metformin, and emerging candidates including senolytics, SGLT2 inhibitors, and GLP-1 receptor agonists. The review concludes with a call for multiomics and AI-driven deep phenotyping to stratify arterial stiffness endotypes and develop truly personalized interventions.